trial

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder

NCTId NCT00035802
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 13 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2002-01
Primary completion
—
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
topiramate

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
13
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
topiramate
drug
lead_sponsor
Johnson & Johnson
company
indication
Mania
indication
Bipolar Disorder
indication
Affective Disorders, Psychotic
indication